WHITE PLAINS, N.Y., Dec. 23, 2024 — Royal Health Inc, a leading provider of advanced radiology software and workflow solutions, today announced the successful close of a minority investment, led by HealthQuest Capital, a leading growth capital firm focused on investing in transformative healthcare companies. Although the funding amount remains undisclosed, this recapitalization resulted in a near eightfold increase in enterprise valuation since the entry of Royal Health’s 2019 investors.

This strategic investment will enable Royal Health to scale its operations. It will also enhance the company’s technology offerings. Additionally, it will support expansion in both U.S. and international markets.

Royal Health is renowned for pioneering solutions that optimize radiology workflows and elevate patient care. The company is well-positioned to lead innovation in an industry experiencing rapid transformation.

Peter Nassif, CEO and Founder of Royal Health Inc, commented:
“This partnership with HealthQuest Capital represents a significant milestone for Royal. Their expertise and shared commitment to advancing healthcare align perfectly with our mission to revolutionize radiology with smarter, more efficient solutions. This investment will allow us to accelerate delivering exceptional value to imaging centers, healthcare providers and patients”

HealthQuest Capital’s investment reflects its confidence in Royal Health’s ability to address critical challenges in radiology, including operational efficiency, staffing shortages, and improving the patient’s experience.

Sharath Reddy, Partner at HealthQuest Capital, stated:
“Royal Health Inc is at the forefront of transforming radiology with cutting-edge technology that enhances workflows and delivers better outcomes for both patients and providers. We’re proud to support their continued growth and innovation as they redefine the future of radiology.”

The investment will drive advancements in Royal Health’s product portfolio. It will also accelerate research and development efforts. Additionally, it will enhance the company’s ability to support healthcare providers navigating complex radiology landscapes.

Peter Nassif concluded:

“This marks an exciting new chapter for Royal Health. With HealthQuest Capital’s partnership, we are poised to accelerate innovation, expand our reach, and continue delivering cutting-edge solutions that transform radiology. Together, we’ll empower providers to operate more efficiently and improve the patient experience, shaping the future of healthcare.”

About Royal Health Inc

Royal Health Inc delivers innovative, cloud-based workflow solutions tailored for healthcare providers, particularly in radiology. With a full suite of integrated tools spanning the entire radiology workflow—from pre-visit processes through to revenue cycle and analytics—Royal Health enables organizations to streamline operations and elevate quality of care. Royal Health is known for its customer-focused approach and scalable solutions. The company is dedicated to driving efficiency and reliability for healthcare providers of all sizes including both independent facilities and complex, multi-site systems.

About HealthQuest Capital

HealthQuest Capital is a private asset firm that provides capital to transformative healthcare companies. HealthQuest Capital focuses on commercial prospects that drive enhanced patient outcomes and elevate the efficiency of healthcare delivery. With approximately $2 billion in capital under management, the firm focuses on fostering innovation across the healthcare spectrum, including medical technologies, diagnostics, digital health, and innovative services. The HealthQuest Capital team combines decades of investing experience with domain expertise in the various aspects of the healthcare industry. For more information, visit www.healthquestcapital.com.

For more information, visit https://royalemr.com/ or contact 347-773-2219 or [email protected].

SOURCE Royal Health Inc

AI-Based Intelligent Automation Leader to Accelerate Innovation, Invest in Customer Success and Expand Market Reach

AUBURN, Calif., Dec. 23, 2024 — HuLoop Automation, the leader in radically simple, fast, and affordable AI-powered intelligent automation, today announced the successful closing of its Series A funding round.  While the specific terms aren’t being announced publicly, the round was led by San Francisco, California-based Mighty Capital, with significant participation from Folsom, California-based Moneta Ventures, which led HuLoop’s prior round.

This funding marks a major milestone for HuLoop as it accelerates its mission to simplify automation and empower businesses in key underserved segments like banks, credit unions, collections and retail enterprises. The investment will fuel the expansion of its team, enhance its unified automation platform, and drive customer growth and expansion.

“At HuLoop, we are committed to transforming key industries by making intelligent automation radically simple, fast, and affordable for businesses of all sizes,” said Todd P. Michaud, CEO of HuLoop Automation. “This latest round positions HuLoop to achieve even faster growth, faster innovation, and greater benefits for our customers.”

“HuLoop’s innovative approach, which blends cutting-edge AI with human-in-the-loop processes, represents the future of intelligent automation. Mighty Capital invests in companies with exceptional products because we believe the best product wins, and HuLoop is no exception,” said SC Moatti, Founder and Managing Partner at Mighty Capital.

Moatti, who also founded Products That Count, a large, global network of product managers, leverages this network to identify and invest in emerging innovation companies with strong product-focused strategies. “Our members are very focused on vertical AI solutions, particularly those centered on shaping the future-of-work and we believe that HuLoop is well-positioned to fill this market need,” said Moetti.

HuLoop defines its Unified Automation Platform as a single, integrated solution that combines multiple automation technologies—such as robotic process automation (RPA), workflow orchestration, intelligent document processing, and testing—into a cohesive system. This platform enables organizations to streamline complex business processes, reduce manual effort, and drive efficiency across the enterprise, while ensuring human-in-the-loop oversight to balance automation with human judgment.  The company has grown rapidly over the past two years, now serving more than 60 customers primarily in the financial services and commerce sectors.

“HuLoop’s success in the community banking sector reflects a pragmatic, cost-effective approach to technology adoption for productivity gains,” said Charles Potts, executive vice president and chief innovation officer for the Independent Community Bankers of America. “By combining automation with human intelligence, their human-in-the-loop process streamlines mundane tasks, allowing staff to focus on more critical customer interactions.”

The capital infusion will be primarily focused on helping HuLoop to accelerate product innovation, invest in customer success, and expand its market reach, helping customers’ companies unlock their productivity potential.

“I’d like to thank Mighty Capital, Moneta Ventures, our Founding Stakeholders, and all our investors for their belief and confidence in HuLoop. Your financial and strategic support is going to help us deliver innovative automation solutions that drive more success for our clients,” said Michaud.

About HuLoop Automation
HuLoop Automation delivers AI-powered intelligent automation solutions designed to boost productivity for companies of all sizes. Its Unified Automation platform provides businesses with tools to discover, automate, and test processes seamlessly. The platform includes three core modules: Intelligent Productivity Discovery, which empowers organizations to identify and prioritize automation opportunities with actionable insights; Intelligent Process Automation, which streamlines workflows by automating repetitive, manual tasks across systems and departments; and Intelligent Test Automation, which enhances quality assurance with automated testing for software, ensuring faster deployment cycles and higher reliability.

HuLoop’s no-code platform leverages advanced technologies such as process and task mining, robotic process automation (RPA), intelligent document processing (IDP), workflow, automated testing, using applied and generative AI, and complemented by human-in-the-loop features. These innovations enable businesses to achieve new levels of efficiency and success, empowering their workforce to focus on high-value tasks and drive transformative outcomes.

Media Contact:
Erin Leventhal
(858) 522-0357
[email protected]

SOURCE HuLoop Automation, Inc.

BROOKLYN, N.Y., Dec. 20, 2024 — Today, Brooklyn Artificial Intelligence Research (“Brooklyn“) announced the closing of a strategic funding round led by Atypical Ventures, with participation from S&P Global Ventures, the CEO of the Hantz Group, and asset and wealth management executives.

Brooklyn’s innovative multi-asset direct indexing platform enables asset managers and independent RIAs to scale personalization and tax management across equities and fixed income within a single custodian account. The platform is delivered either as a white-label technology solution or as a subadvisory service through Brooklyn Investment Group, LLC, a registered investment adviser.

“Our vision is that tech-powered managed accounts will fundamentally transform the asset management industry,” said Erkko Etula, CEO and Co-Founder of Brooklyn. “As the demand for our platform continues to accelerate, strategic alignment with investors who share this vision will strengthen our ability to serve clients and to advance the industry-wide shift toward personalized and tax-managed investing.”

“At Atypical, we invest early in transformative companies and stay deeply engaged throughout their journey. Brooklyn exemplifies our approach—a non-obvious technical advantage paired with an empathetic team that is delivering tangible client value,” said Chris Wake, Managing Partner at Atypical. “We’re proud to have catalyzed this round to scale Brooklyn’s platform and expand its positive-sum impact, empowering asset managers and growing the market for personalized, tax-managed investing.”

“Technology is the new wrapper for customized portfolios,” added Erkko Etula. “Unlike ETFs and mutual funds, our tech-powered managed accounts ecosystem enables our investment advisors to deliver customized investment solutions and tax alpha across equities and fixed income to each client, while continuing to scale growth.”

In September this year, Brooklyn Investment Group and S&P Dow Jones Indices (“S&P DJI”), a division of S&P Global, announced the launch of MyIndex, a customizable version of S&P DJI’s market-leading indices offering, on Brooklyn’s managed accounts platform.

“S&P Global is pleased to support this stage of Brooklyn Artificial Intelligence Research’s growth,” said Dan Draper, Chief Executive Officer at S&P Dow Jones Indices. “This investment aligns with our company’s commitment to power the markets of the future by offering innovative ways to expand access to our trusted benchmarks and data, addressing the evolving needs of the next generation of investors and market participants.”

Brooklyn’s client base features dozens of RIA firms, as well as asset managers whose assets total over $2 trillion.

To learn more about the BKLN, its technology, and career opportunities, visit BKLN.com, LinkedIn, or reach out to us at [email protected].

About Brooklyn Artificial Intelligence Research and Brooklyn Investment Group, LLC:

Brooklyn Investment Group is an SEC-registered investment adviser that combines artificial intelligence with institutional-grade portfolio optimization and automated tax-loss harvesting to power personalized portfolios for its clients, which include asset and wealth management firms. Registration with the SEC does not imply a certain level of skill or training, nor does it constitute an endorsement by the SEC. Brooklyn Investment Group is wholly-owned by Brooklyn Artificial Intelligence Research (d/b/a of Skopos Labs, Inc.), a technology company.

The information contained above is provided for informational and educational purposes only. It does not constitute an offer for either services or investment, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. By this release, Brooklyn Investment Group, its affiliates, and its licensors do not make any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results, and all investment strategies involve the risk of loss. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

Media Contact: [email protected]

SOURCE Brooklyn Investment Group

The round is led by Lux Capital, with participation from Elad Gil, Anthropic & Menlo Ventures Anthology Fund, McKesson Ventures, Avichal Garg/Electric Capital, Moxxie Ventures, Carbon Silicon Ventures, and leaders in AI and life sciences – Othman Laraki (CEO Color Health), Fidji Simo (CEO Instacart, Co-founder Metrodora Institute, OpenAI Board), Mike Nohaile (CEO Prellis Biologics, previously Amgen & Novartis Executive), Kristen Fortney (CEO BioAge), Eric Morgen (COO BioAge), Qasar Younis (CEO Applied Intuition), Linus Upson (Verily), and Jeffrey Low (Life sciences investor).

“At Lux, we fund businesses that turn science fiction into fact. Bluenote is enabling exactly that type of breakthrough innovation—leveraging cutting edge AI to radically reduce the overhead and manual workflows to bring pharmaceutical products into the hands of patients sooner,” said Deena Shakir, General Partner at Lux Capital. “The team represents inimitable industry expertise and technical sophistication, and their traction and high praise from customers speak for itself.”

Bluenote’s Generative AI Technology Platform Streamlines Regulatory & Compliance Workflows

Companies in the life sciences industry are heavily regulated, and need to invest significant time and resources to fulfill their regulatory and compliance obligations. While the regulatory framework is in place to ensure patient safety, clinical efficacy, and consistent product quality, the work required to produce compliance documentation is time-consuming and largely manual. Following a clinical trial’s completion, companies typically spend 8-9 months preparing regulatory submissions¹. Across the industry, thousands of scientists, engineers, and development professionals spanning multiple functions – research, clinical, manufacturing, regulatory and quality – dedicate significant time to produce thousands of pages for regulatory filings and manage complex interdependencies between protocols, technical reports and compliance requirements. This time could instead be redirected towards scientific research and product development to bring new breakthroughs to patients.

Bluenote has developed a generative AI technology platform for life sciences companies to streamline regulatory workflows and bring their breakthroughs to patients sooner. Today, the platform’s most widely used applications focus on producing regulatory filings, technical reports, protocols, Standard Operating Procedures (SOPs), validation reports, risk analyses, manufacturing documentation and more. Bluenote has deployed 15+ applications for scientists, engineers, quality, regulatory and manufacturing teams. Bluenote has developed fine-tuned models that are 90% preferred over off-the-shelf models. The company is rapidly expanding the number of applications on its platform.

Bluenote is Increasing the Accuracy, Reliability & Timeliness of Regulatory Filings, and Helping Companies Accelerate Time to Market

“Within the healthcare industry, we face extensive regulatory requirements and documentation that must adhere to numerous guidelines and regional laws. At Guardant Health, we have been pleased with Bluenote’s generative AI capabilities to streamline these time-intensive and complex tasks—ranging from scientific research papers, study reports, and software development documentation critical to regulatory filings,” said Kenny Speer, Vice President, Bioinformatics and Software Engineering at Guardant Health. “Bluenote’s technology not only helps the accuracy, reliability, and timeliness of our documentation, but also flags areas that need human-in-the-loop review. This heightened confidence in our submissions ultimately improves completeness, reduces time-to-market, and supports better patient care outcomes.”

“Companies spend an inordinate amount of time and resources producing thousands of pages for regulatory filings. Hundreds of people are involved across R&D, clinical, manufacturing, regulatory,” said Mike Nohaile, CEO of Prellis Biologics, and previously executive at Amgen and Novartis. “Every week a process development scientist spends on documentation is a week they are not optimizing the drug product. You want your clinical teams focused on opening study sites, not filling in regulatory filings. Now companies can automate this time-intensive work with Bluenote, and focus on critical development activities.”

“Life sciences leaders are moving quickly to deploy generative AI across dozens of workflows. In this industry, every day counts. Each day a breakthrough therapy or device is not in the hands of clinicians and patients is a lost opportunity to save lives,” said Fatima Sabar, Bluenote Co-founder & CEO. “Bluenote’s AI agents are being integrated into laborious workflows to accelerate time to market and increase operational excellence.”

Bluenote has Developed a Secure Generative AI Platform that is Tailored to the Life Sciences Industry:

• Accuracy and verifiability of AI outputs
  • Bluenote’s product is engineered to include only factual details from traceable primary sources, combining guardrails with custom Large Language Models (LLMs), and inserting call-to-action placeholders for human reviewers to provide details where additional context is needed.
• Customized outputs via proprietary datasets, connectivity to data lakes & a multi-model approach
  • Bluenote developed domain-optimized Retrieval-Augmented Generation (RAG) that ingests data from various data lakes and third party applications, accurately processes the datasets, including industry-specific edge cases, and indexes them to support unique application requirements.
  • Bluenote finds that there is no one-size-fits-all model, and instead, combines the best models from Anthropic, OpenAI, Google, and its own fine-tuned models based on proprietary datasets. With new models regularly entering the market, Bluenote continuously evaluates and updates model configurations to ensure that customers are among the first to benefit from the latest advances.
• Single, secure platform that powers multiple workflows and functions
  • There are compounding benefits to having a single platform running AI applications instead of multiple vendors for each. The same proprietary knowledge base is used for multiple applications. The outputs from one workflow become inputs into another, enabling the propagation of changes. In addition, customers prefer to consolidate their proprietary data within a single, secure environment for simplicity.

With the new financing, Bluenote is rapidly expanding its platform to support additional mission-critical, time-intensive workflows, and enabling life sciences companies to bring their breakthroughs to patients sooner.

Life sciences leaders can request a demo at https://www.bluenotehealth.com/.

¹ [Article] Getting strategic about new-product submissions in the pharma industry.

Contact:
Fatima Sabar
[email protected]

SOURCE Bluenote

• The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the “Tkumah” administration, post-war.
• The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders.
• Funding also includes a loan from a major Israeli bank.
• Completing the post-war damage recovery processes will enable the company to return to profitable growth without further delay, including exercising the cookies agreement and expanding international operations in Germany, the UK, and Australia.
• The Company anticipates receiving additional substantial payments from the Israeli authorities, as part of the full compensation for war related damages, including loss of profits the Company is entitled to.

NEW YORK and HERZLIYA, Israel, Dec. 20, 2024 — InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company“), is pleased to announce that further to the Company’s prior reports regarding the war-related damages and the reconstruction efforts of its facility in Kibbutz Nir Oz, the Company was successful in obtaining funding commitments of NIS 66 million (approximately USD 18.2M), which may increase to NIS 107 million (approximately USD 29.8M).

The funding includes a commitment by certain investors, including the Company’s Chief Executive Officer, Mr. Alexander Rabinovich, and two existing shareholders, Mr. Yaron Yakobi and Mr. Tzahi Hagag, who, as a result of the investment, will each hold more than 5% of the Company’s issued and outstanding share capital (collectively, the “Investors”) to purchase ordinary shares of the Company by way of a private placement (the “Private Placement”). In the Private Placement, InterCure has agreed to issue to the Investors (i) an aggregate of 7,349,896 ordinary shares of the Company, at a purchase price of NIS 4.83 (approximately USD 1.34) per ordinary share, at a premium above the opening price of InterCure’s ordinary shares on the Tel Aviv Stock Exchange on the morning of Monday, December 16, 2024, which was NIS 4.81 per share (the “Determining Date”) and (ii) warrants (the “Warrants”) to purchase up to an additional 7,349,896 ordinary shares of the Company at an exercise price equal to NIS 5.70 (approximately USD 1.58) (the “Exercise Price”), at an 18% premium above the opening price of InterCure’s ordinary shares on the Determining Date, which may further increase the proceeds from the Private Placement up to a total of approximately NIS 77 million (approximately USD 21.5M) if the Warrants are fully exercised in cash. All of the issued securities shall be restricted under the Nasdaq rules. The consideration for the allocated securities was determined through negotiations between the Company and the Investors, based on the opening share price on the Determining Date. The Private Placement is subject to certain closing conditions, which include the approval of the shareholders of the Company.

In addition, the Company received a binding commitment from one of the leading banks in Israel, to provide the Company with a loan of NIS 30M (approximately USD 8.3M), for a period of up to 24 months (the “Loan”). The Loan is subject to certain closing conditions, including closing the Private Placement.

“This investment marks a pivotal moment for InterCure, delivering the momentum needed to reignite our growth and drive us forward,” said Alexander Rabinovich, CEO of InterCure. “Following a challenging period with our Southern Facility in Kibbutz Nir Oz, this funding, represents a huge vote of confidence from investors who believe in the Company’s growth strategy, alongside one of the leading banks in Israel. We believe this investment will enable us to strengthen our position in Israel and drive our expansion into key international markets, with a focus on Europe and Germany particularly. We remain hopeful for a swift end to the ongoing war and the return of all hostages, including our employees and our close friends from the kibbutzim surrounding the Gaza strip, to their homes and we are confident in our ability to contribute significantly to the post-war recovery efforts of such area. We expect that this funding will empower us to complete our recovery, and drive InterCure’s return to growth and profitability through the year 2025.”  

Under Israeli law, the Company’s Southern Facility, located in an area impacted by the terrorist attack and the war in Gaza, is entitled to full compensation for all direct and indirect damages incurred, including loss of profits. To date, the Company has received advance payments totaling tens of millions of NIS from Israeli authorities as part of this compensation. These advances, which represent only a small portion of the Company’s total damages, have supported the initial phases of the ongoing restoration efforts. However, given the prolongation of the war and the fact that the last significant advance was received from the Israeli authorities only in April 2024, the current funding, will enable the Company to successfully advance its recovery and restoration efforts without further delays. We expect that this funding will position the Company to return to the growth and profitability rates it achieved prior to the war, during the year 2025. The Company anticipates receiving additional substantial payments from the Israeli authorities, to which the Company is entitled to, and is working closely with its professional advisors and the authorities to receive these payments.

Additionally, in collaboration with “Tkumah Administration” and other authorities in Israel, the Company is working to significantly develop and expand its Southern Facility immediately upon the conclusion of the Gaza war as part of its recovery efforts for the kibbutzim surrounding the Gaza strip. This expansion aligns with InterCure’s global growth strategy, which includes doubling production capacity in Israel and enhancing our portfolio of high-quality products using advanced technologies, targeted at developing markets globally, including Germany, the UK, Australia, and more.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the ordinary shares or warrants in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit www.intercure.co.

Forward–Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements may include, but are not limited to, the Company’s success of its global expansion plans, its expansion strategy to major markets worldwide, the inability to successful complete the proposed transaction; statements relating to the security events in Israel, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the successful completion of the proposed transactions, the Company’s success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic, the impact of the war in Israel and the war in Ukraine and the conditions of the markets generally. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
[email protected]

Logo: https://mma.prnewswire.com/media/2585916/InterCure_Logo.jpg

SOURCE InterCure Ltd.

NEW YORK, Dec. 20, 2024 — Jackson Rose, a venture capital firm, is proud to announce its participation in Tenstorrent’s Series D funding round alongside Bezos Expeditions, LG Electronics, and Hyundai Motor Group. The round was led by Samsung Securities and AFW Partners. Other investors in the round include Fidelity Management, Healthcare of Ontario Pension Plan, and Baillie Gifford. Tenstorrent raised over $693M in its Series D round at a pre-money valuation of $2B.

“We are excited to be working with Jackson Rose to scale our business for the future,” said Keith Witek, Chief Operating Officer of Tenstorrent. “Jackson Rose is part of the syndicate of investors that gives Tenstorrent a balance of financial investors, industry luminaries, and strategic investors that are all unified in their conviction of our plans for AI. They respect our team, our technology, and our vision. They see the ~$150M in deals closed as a strong signal of commercial traction and opportunity in the market.”

Tenstorrent will use the Series D funding to build out open-source AI software stacks, hire developers, expand its global development and design centers, and build systems and clouds for AI developers.

“Our investors are great,” said Jim Keller, CEO of Tenstorrent. “During the fundraising process I was impressed by how interested our investors were in our open-source approach to software. They realize that the way to win is to get developers on board by giving them all the tools they need to own their own technology.”

About Tenstorrent

Tenstorrent is a next-generation computing company that builds computers for AI. Tenstorrent is headquartered in North America and has locations in Toronto, Austin, and Silicon Valley, and global offices in Belgrade, Tokyo, Bangalore, Singapore, and Seoul. Tenstorrent brings together experts in the fields of AI software, computer architecture, silicon design, and advanced systems. Tenstorrent is backed by Eclipse Ventures and Real Ventures, among others. Learn more @ tenstorrent.com.

About Jackson Rose

Jackson Rose is a venture capital firm headquartered in New Jersey. For more information, please email [email protected].

SOURCE Jackson Rose

SINGAPORE, Dec. 20, 2024 — bolttech, the fast-growing global insurtech, today announced Dragon Fund, by Liquidity and MUFG, is leading bolttech’s Series C funding round alongside investors Baillie Gifford, Generali – through Lion River, the Group’s company dedicated to Private Equity, and others, which is expected to total more than US$100 million. Following bolttech’s record-breaking Series A and B rounds, the Series C up-round values bolttech at US$2.1 billion and the investment will further enhance its global growth strategy.

The strategic support of lead investor Dragon Fund alongside the follow-on investors and the Series C funding will enable bolttech to continue to enhance its platform’s capabilities, expand its market presence globally, and accelerate its goal to make insurance more tailored, accessible, affordable and convenient for customers. This investment follows bolttech’s previous successful funding rounds, further establishing its role as a leader in the insurtech space.

Ridhi Chaudhary, CIO of Dragon Fund, said, “We are excited to lead bolttech’s Series C round. In a short time, bolttech has become a leading, embedded insurtech player with global presence and scale. We are impressed by its tech capabilities and execution. I look forward to joining the Board of Directors and supporting its next phase of growth.”

Aakash Tulsani, Managing Director at Dragon Fund, added, “bolttech’s differentiated technology and program management solution integrates insurance into customer purchase journeys, enhancing access to affordable, customized products. As a technology-first provider, bolttech is well positioned to shape the future of embedded insurance a $70B+ addressable market globally.”

Hendrik Borginon, Investment Manager, Baillie Gifford, said, “bolttech is a pioneering force in the embedded insurance space. By enabling seamless integration of insurance products into their distribution partners, bolttech is transforming how insurance is bought and sold globally. With a highly experienced team at the helm, we are optimistic about their potential to drive significant growth and profitability in the coming years.”

Rob Schimek, Group Chief Executive Officer, bolttech, said, “This latest round of funding is an endorsement of our value proposition and marks another significant milestone for bolttech. The funding also demonstrates our relentless pursuit of innovation and excellence as we enable the insurance industry. With this investment from Dragon Fund and our Series C investors, we will continue to revolutionise the future of insurance through our leading technology-enabled ecosystem.”

About bolttech
bolttech is a global insurtech with a mission to build the world’s leading, technology-enabled ecosystem for protection and insurance. bolttech serves customers in more than 35 markets across Asia, Europe, North America, and Africa.

With a full suite of digital and data-driven capabilities, bolttech powers connections between insurers, distributors, and customers to make it easier and more efficient to buy and sell insurance and protection products.

For more information, please visit: www.bolttech.io

About Dragon Fund
Launched in 2023, Dragon Fund, by Liquidity and MUFG, is an equity investment platform that invests globally in growth-stage technology and technology enabled companies. The platform leverages Liquidity’s proprietary technology in its investment process and MUFG’s extensive global network.

For more information, please visit: www.dragonfunds.com

About Baillie Gifford
Baillie Gifford is an independent investment partnership founded over a century ago in Edinburgh, owned and run by 58 partners who all work at the firm. The firm’s mission is to find game-changing companies (both public and private) that can sustain growth and provide returns for clients over five to ten years and longer. With 1,708 staff and assets under management of £218bn, it has offices in Edinburgh, Amsterdam, Dublin, Frankfurt, Hong Kong, London, New York, Shanghai, Toronto, and Zurich (at 30 September 2024). 

About The Generali Group
Generali is one of the largest global insurance and asset management providers. Established in 1831, it is present in over 50 countries in the world, with a total premium income of € 82.5 billion in 2023. With around 82,000 employees serving 70 million customers, the Group has a leading position in Europe and a growing presence in Asia and Latin America. At the heart of Generali’s strategy is its Lifetime Partner commitment to customers, achieved through innovative and personalised solutions, best-in-class customer experience and its digitalised global distribution capabilities. The Group has fully embedded sustainability into all strategic choices, with the aim to create value for all stakeholders while building a fairer and more resilient society.  

SUNNYVALE, Calif., Dec. 19, 2024 — Plug and Play, a global innovation platform that connects startups, corporations, and investors to foster innovation across industries, has announced a new relationship with The Huntington National Bank, a leading regional bank with a strong commitment to customer-centric financial solutions.

“Our collaboration with Plug and Play positions Huntington Bank as an innovator in the financial services sector, allowing us to attract new fintech partnerships and deliver innovative solutions to our customers,” said Igor Cerc, Chief Enterprise Strategy Officer and Head of Ventures at Huntington Bank. “This relationship aims to accelerate the development of emerging technologies and startup ecosystems that will enhance our brand’s visibility and reputation.”

As part of Plug and Play’s fintech program, Huntington Bank will gain exclusive access to cutting-edge technologies and solutions developed by startups in the fintech sector. This collaboration creates opportunities for the bank to explore new business models, boost operational efficiency, and enhance customer experiences.

“Huntington Bank’s involvement in our fintech program will bring critical industry expertise and operational insight to our startups,” said Tevin Panchal, Senior Corporate Partnerships Manager at Plug and Play. “By collaborating with one of the most trusted financial institutions, our startups will gain unique perspectives that will help drive innovation in the financial services sector.”

Plug and Play’s fintech program brings together industry leaders and startups, fostering collaboration and innovation in the financial sector. Through this collaboration, startups will gain access to valuable expertise, mentorship, and growth opportunities.

To learn more about Plug and Play Fintech, visit https://www.plugandplaytechcenter.com/industries/fintech.

About Plug and Play

Plug and Play is the leading innovation platform, connecting startups, corporations, venture capital firms, universities, and government agencies. Headquartered in Silicon Valley, we’re present in 60+ locations across 5 continents. We offer corporate innovation programs and help our corporate partners in every stage of their innovation journey, from education to execution. We also organize startup acceleration programs and have built an in-house VC to drive innovation across multiple industries where we’ve invested in hundreds of successful companies including Dropbox, Guardant Health, Honey, Lending Club, N26, PayPal, and Rappi. For more information, visit plugandplaytechcenter.com/

Media Relations Contact
[email protected]

SOURCE Plug and Play

Existing Investors Reinforce Confidence in the Industry-Leading Automated Chargeback Management Provider

NEW YORK, Dec. 19, 2024 — Justt, the leader in AI-based chargeback management, today announced the successful close of its $30 million Series C funding round, led by Zeev Ventures with participation from existing investors Oak HC/FT and F2 Venture Capital. This funding highlights the unwavering confidence of its investors in Justt’s vision, sustained growth, and position as a market leader.

With total funding now at $100 million, Justt is advancing its mission to transform chargeback management through its proprietary AI technology and in-house expertise. The company’s scalable platform, designed for merchants of all sizes, is reshaping how payment disputes are resolved, helping businesses recover lost revenue, reduce complexity, and drive operational efficiency.

Fueling Expansion and Chargeback Innovation

This funding will drive Justt’s strategic expansion into high-growth regions, while advancing its path to profitability by 2027. The company will enhance its proprietary AI-driven platform, which analyzes over 500 data points from multiple sources to create tailored, high-quality arguments for each case. This dynamic system leverages machine learning to optimize dispute win rates and continuously improve outcomes over time.

Justt’s commitment to innovation and excellence has made it the trusted partner of over 200 clients, including some of the biggest names in global e-commerce.

“Justt’s advanced AI and machine learning-driven approach is revolutionizing chargeback management, providing merchants with a scalable, results-driven solution to navigate an increasingly complex payments landscape,” said Oren Zeev, Founding Partner at Zeev Ventures. “Justt’s ability to execute, innovate, and deliver measurable value to merchants worldwide is unmatched. This funding underscores my confidence in their vision, leadership, and long-term strategy as they continue to expand globally and redefine the industry.”

Momentum Built on Growth and Client Success

Since Justt’s Series B in 2021, the company has demonstrated extraordinary growth. Revenue tripled in 2023 and grew more than 2X in 2024. Building on this momentum, Justt is projected to double its revenue year-over-year in both 2025 and 2026.

In 2024, Justt nearly doubled the total chargeback volume it managed compared to the previous year, reflecting the platform’s growing adoption and scalability. Additionally, merchants who switched to Justt—whether from in-house teams or other solutions—recovered nearly twice as much revenue on average, demonstrating the superior results delivered by Justt’s technology.

“Justt’s ability to scale with our clients without compromising quality, and drive continuously improving results through advanced machine learning is what sets us apart in the industry,” said Ofir Tahor, CEO and Co-Founder of Justt. “This funding will drive our global expansion, fuel technological advancements, and further our mission to help merchants resolve payment disputes more efficiently and recover more revenue.”

Global Presence

In 2024, Justt expanded its global footprint by opening offices in New York and London, complementing its established R&D hub in Tel Aviv. The London office addresses growing demand in the UK and EMEA regions, helping merchants navigate increasingly complex and diverse payment ecosystems. Meanwhile, the New York headquarters enhances Justt’s capacity to serve its expanding North American client base, the world’s largest and most dynamic e-commerce market.

These strategic expansions strengthen Justt’s ability to scale and deliver tailored solutions across industries and geographies. They also position the company for continued growth as it prepares to enter high-growth regions such as LATAM and APAC.

About Justt

Founded in 2020, Justt is the world’s first smart chargeback solution that tailors each response and improves over time. Unlike template-based solutions, it uses AI-powered automation and domain expertise to generate dynamic arguments, customizing each response, no matter the volume or complexity. With a machine learning engine that’s continuously running A/B tests in the background, Justt is the only chargeback solution that self-improves over time—helping merchants win more disputes effortlessly. https://justt.ai/

SOURCE Justt